Pemetrexed

BNF:
8.1.3
Status:
Red
Decision Date:
September 2016
 

Comments

RED 1,2,3: NICE TA402: Pemetrexed maintenance treatment  for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin.

(NHSE is the responsible commissioner for this drug. From August 2016 Pemetrexed will be available through routine commissioning).

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app